The startup specializing in robotics for early patient mobilization ReActive Robotics has closed a seven-figure Series A financing round. Investors in this financing round include Bavaria Capital MTIP MedTech Innovation Partners AG, the TQ-Group and the High-Tech Gründerfonds (HTGF).
With the provided capital, Munich-based ReActive Robotics GmbH plans to develop several prototypes for clinical trials in 2017. The market size is estimated at over two billion euros. The device will be launched in Europe in early 2018.
The robotic modules developed by ReActive Robotics enable automated early mobilization of severely ill patients – even in the intensive care unit, just 24 hours after admission. Thanks to the intelligent, flexible technology, the modules can be attached to the bedside and used to mobilize intensive care patients by just one nurse. This eliminates the risk of transferring the patient to another therapy device, and it relieves therapists of the hard work of therapy and eliminates the need for additional nurses. ReActive Robotics' intelligent early mobilization system thus contributes to cost-reduced, improved patient care.
"ReActive Robotics' innovative product development has convinced us from the very beginning. It is already clear that the product, which will initially be used in intensive care units, has numerous other applications,"
explained Dr. Georg Ried, Managing Director of Bayern Kapital.
"The extensive technical expertise of the ReActive Robotics founding team, led by Dr. Alexander König, has impressed us deeply and allows us to make a very positive prognosis for the company."
Dr. Alexander König, CEO and founder of ReActive Robotic, explains:
"Due to demographic change and rising healthcare costs, our society needs intelligent automation solutions in the treatment and care of severely ill patients. With the additional capital, we can develop a clinical prototype series and validate our concept of robot-assisted early mobilization in the intensive care unit."
